AU2020374878B2 - Anti-hemagglutinin antibodies and methods of use thereof - Google Patents

Anti-hemagglutinin antibodies and methods of use thereof

Info

Publication number
AU2020374878B2
AU2020374878B2 AU2020374878A AU2020374878A AU2020374878B2 AU 2020374878 B2 AU2020374878 B2 AU 2020374878B2 AU 2020374878 A AU2020374878 A AU 2020374878A AU 2020374878 A AU2020374878 A AU 2020374878A AU 2020374878 B2 AU2020374878 B2 AU 2020374878B2
Authority
AU
Australia
Prior art keywords
antibody
influenza
antigen
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020374878A
Other languages
English (en)
Other versions
AU2020374878A1 (en
Inventor
Alina Baum
Christos Kyratsous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2020374878A1 publication Critical patent/AU2020374878A1/en
Application granted granted Critical
Publication of AU2020374878B2 publication Critical patent/AU2020374878B2/en
Priority to AU2025271140A priority Critical patent/AU2025271140A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
AU2020374878A 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof Active AU2020374878B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025271140A AU2025271140A1 (en) 2019-10-28 2025-11-21 Anti-hemagglutinin antibodies and methods of use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US62/926,914 2019-10-28
US202063094170P 2020-10-20 2020-10-20
US63/094,170 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025271140A Division AU2025271140A1 (en) 2019-10-28 2025-11-21 Anti-hemagglutinin antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2020374878A1 AU2020374878A1 (en) 2022-04-28
AU2020374878B2 true AU2020374878B2 (en) 2025-10-16

Family

ID=73498317

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020374878A Active AU2020374878B2 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof
AU2025271140A Pending AU2025271140A1 (en) 2019-10-28 2025-11-21 Anti-hemagglutinin antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025271140A Pending AU2025271140A1 (en) 2019-10-28 2025-11-21 Anti-hemagglutinin antibodies and methods of use thereof

Country Status (14)

Country Link
US (2) US11773156B2 (enExample)
EP (1) EP4051707A1 (enExample)
JP (1) JP7611908B2 (enExample)
KR (1) KR20220088446A (enExample)
CN (1) CN114761428A (enExample)
AU (2) AU2020374878B2 (enExample)
BR (1) BR112022007923A2 (enExample)
CA (1) CA3153944A1 (enExample)
CL (1) CL2022001067A1 (enExample)
CO (1) CO2022005281A2 (enExample)
IL (1) IL292353A (enExample)
MY (1) MY207220A (enExample)
PH (1) PH12022550963A1 (enExample)
WO (1) WO2021086899A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
WO2015120097A2 (en) * 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US20150274812A1 (en) * 2014-03-27 2015-10-01 Genentech, Inc. Anti-influenza b virus hemagglutinin antibodies and methods of use
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
WO2016196470A1 (en) * 2015-06-01 2016-12-08 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
US20170189529A1 (en) * 2014-02-04 2017-07-06 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EP3305811A1 (en) * 2015-06-03 2018-04-11 Xiamen University Broad-spectrum monoclonal anti-flu b antibody and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EP2825036B1 (en) * 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MX2018015755A (es) * 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) * 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11780907B2 (en) * 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
WO2015120097A2 (en) * 2014-02-04 2015-08-13 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US20170189529A1 (en) * 2014-02-04 2017-07-06 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US20150274812A1 (en) * 2014-03-27 2015-10-01 Genentech, Inc. Anti-influenza b virus hemagglutinin antibodies and methods of use
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
WO2016196470A1 (en) * 2015-06-01 2016-12-08 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
EP3305811A1 (en) * 2015-06-03 2018-04-11 Xiamen University Broad-spectrum monoclonal anti-flu b antibody and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEN C. ET AL: "A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses", Science Translational Medicine, 2017, vol. 9, no. 412, eaam5752, doi: 10.1126/scitranslmed.aam5752 *
YASUGI M. ET AL: "Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus", PLoS Pathogens, 2013, vol. 9, no. 2, article no. e1003150 - 1 doi: 10.1371/JOURNAL.PPAT.1003150 *

Also Published As

Publication number Publication date
CO2022005281A2 (es) 2022-05-10
US11773156B2 (en) 2023-10-03
US20210171612A1 (en) 2021-06-10
IL292353A (en) 2022-06-01
US20240083983A1 (en) 2024-03-14
CA3153944A1 (en) 2021-05-06
JP2022553703A (ja) 2022-12-26
JP7611908B2 (ja) 2025-01-10
CL2022001067A1 (es) 2023-01-27
AU2020374878A1 (en) 2022-04-28
WO2021086899A1 (en) 2021-05-06
KR20220088446A (ko) 2022-06-27
EP4051707A1 (en) 2022-09-07
MY207220A (en) 2025-02-06
CN114761428A (zh) 2022-07-15
BR112022007923A2 (pt) 2022-07-26
PH12022550963A1 (en) 2023-09-25
AU2025271140A1 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
US11453714B2 (en) Human antibodies to influenza hemagglutinin
AU2016211783B2 (en) Human antibodies to Ebola virus glycoprotein
US11780907B2 (en) Human antibodies to influenza hemagglutinin
AU2025271140A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
EA046393B1 (ru) Антитела к гемагглютинину и их применение
EA044791B1 (ru) Человеческие антитела к гемагглютинину вируса гриппа

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)